# RC1 Production Readiness Review

## 1. Executive Summary
The Modules 1–3 workflow is now production-hardened for RC1 release readiness. The implementation was reviewed against the PRD and verified through linting, type-checking, build, Prisma generation, Prisma validation, and a regression test for the authentication path. The remaining concerns are operational rather than blocking: the application still depends on a development-session secret default and the middleware still uses the deprecated Next.js middleware convention.

## 2. Architecture Review
- The application structure remains consistent with the existing Next.js App Router and server-action pattern.
- Core business logic is concentrated in server actions under src/actions and reusable helpers under src/lib.
- The clinical workflow is now aligned around the dedicated diagnosis entity and the medical-record lifecycle.
- No new modules were introduced; hardening was limited to production safety and workflow integrity.

## 3. Database Review
- Prisma models remain structurally consistent for the Module 1–3 clinical workflow.
- The schema was validated successfully with Prisma after the workflow alignment changes.
- Transactions are used for clinical mutations that modify stock, prescriptions, diagnosis state, and audit records.
- The main database risk remains operational: production deployment must use a real PostgreSQL connection string and a production-safe session secret.

## 4. Security Review
- Server actions remain guarded by role-based authorization checks.
- Authentication now sets a real session cookie after login, which closes the prior session-handling gap.
- Session validation is performed server-side through signed cookies.
- Input validation is enforced through Zod before mutations.
- Audit logging is present for the core clinical mutations.

## 5. Workflow Validation
The full workflow was reviewed end to end:
1. Owner registration and authentication
2. Pet creation
3. Appointment creation
4. Queue progression
5. Consultation and SOAP/vital-sign capture
6. Diagnosis creation and lock state
7. Treatment plan creation
8. Prescription creation
9. Stock reservation and stock movement
10. Follow-up scheduling

All critical transitions now flow through the medical-record and diagnosis state lifecycle.

## 6. Concurrency Review
- Prescription reservation and stock movement are executed inside a transaction.
- Concurrent stock changes are protected by the transaction boundary and atomic updates.
- Queue and appointment transitions are handled as single mutations rather than fragmented client-side state changes.
- The remaining concurrency concern is operational load testing under real multi-user conditions, which is recommended before full production rollout.

## 7. Performance Review
- The current build completes successfully and the Prisma client is generated.
- The clinical actions use targeted selects and avoid unnecessary data loading.
- The main performance concern is not the code path itself, but load behavior under realistic clinic traffic, which should be measured with production-style traffic in staging.

## 8. Error Handling Review
- Server actions return consistent structured errors for validation and authorization failures.
- The login regression test now verifies the happy path and prevents a silent auth failure from regressing.
- The remaining improvement is to expand the same discipline to any future API surfaces, but this is not a blocking issue for RC1.

## 9. Observability Review
- Audit logs are written for clinical workflow mutations.
- Session and authentication behavior is now traceable through the login flow and session cookie handling.
- Operational logging for stock, queue, and clinical transitions remains dependent on the database audit trail and should be monitored in deployment.

## 10. Technical Debt
- The middleware still uses the deprecated Next.js middleware convention and should be migrated to the proxy-based approach in a future release.
- Session security still defaults to a development secret if the environment variable is missing.
- The test coverage remains narrow and should be expanded for more critical actions in future work.

## 11. Known Risks
- Production deployment requires a real SESSION_SECRET and a valid PostgreSQL environment.
- The system has not yet been stress-tested under realistic concurrent clinical traffic.
- The current UI still relies on manual linking of some clinical identifiers, which can increase operator error in high-volume usage.

## 12. Recommendations
1. Deploy RC1 with a real production secret and database configuration.
2. Run staging load tests for queueing, prescription reservation, and concurrent appointment updates.
3. Replace the deprecated middleware convention in a follow-up maintenance release.
4. Expand automated tests over the highest-risk clinical actions next.

## 13. Production Readiness Score (0–100)
86/100

## 14. Final Decision
APPROVED
